EYEPOINT PHARMACEUTICALS, INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 11.13 USD | -2.96% |
|
-11.10% | -51.84% |
| May. 08 | Baird Adjusts Price Target on EyePoint Pharmaceuticals to $38 From $46, Keeps Outperform Rating | MT |
| May. 08 | Earnings Flash (EYPT) EYEPOINT PHARMACEUTICALS Posts Q1 Revenue $11.7M | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 167.6 | 99.56 | 414.9 | 119.3 | 1,088 | 597.4 | - | - |
| Enterprise Value (EV) 1 | 167.6 | 99.56 | 414.9 | 119.3 | 806.6 | 382.7 | 249.2 | 106.2 |
| P/E ratio | -2.87 x | -1.86 x | -6.03 x | -1.28 x | -12.7 x | -4.78 x | -3.5 x | -3.46 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 8.23 x | 2.89 x | 11.2 x | 2.88 x | 23.6 x | 14.5 x | 49.1 x | 62.5 x |
| EV / Revenue | 8.23 x | 2.89 x | 11.2 x | 2.88 x | 17.5 x | 9.28 x | 20.5 x | 11.1 x |
| EV / EBITDA | -4.12 x | -2.87 x | - | - | - | 2.39 x | 1.33 x | 0.45 x |
| EV / FCF | -2.94 x | -6.73 x | -8.26 x | -1.78 x | -502 x | -2.78 x | -1.87 x | -0.87 x |
| FCF Yield | -34% | -14.9% | -12.1% | -56.3% | -0.2% | -35.9% | -53.5% | -115% |
| Price to Book | - | - | - | - | 4.26 x | 3.27 x | 2.1 x | 1.72 x |
| Nbr of stocks (in thousands) | 10,812 | 15,130 | 33,894 | 34,083 | 47,074 | 52,084 | - | - |
| Reference price 2 | 15.50 | 6.580 | 12.24 | 3.500 | 23.11 | 11.47 | 11.47 | 11.47 |
| Announcement Date | 3/5/20 | 3/4/21 | 3/3/22 | 3/2/23 | 3/7/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 20.36 | 34.44 | 36.94 | 41.4 | 46.02 | 41.22 | 12.17 | 9.553 |
| EBITDA 1 | -40.69 | -34.64 | - | - | - | 159.9 | 186.9 | 235.3 |
| EBIT 1 | -47.86 | -37.29 | -55.28 | -78.94 | -75.07 | -138 | -192.3 | -200.3 |
| Operating Margin | -235.02% | -108.28% | -149.64% | -190.65% | -163.13% | -334.65% | -1,580.55% | -2,096.36% |
| Earnings before Tax (EBT) 1 | -56.79 | -45.39 | -58.42 | -102.3 | -70.71 | -128 | -190 | -200.8 |
| Net income 1 | -56.79 | -45.39 | -58.42 | -102.3 | -70.8 | -128 | -188.5 | -200.9 |
| Net margin | -278.88% | -131.82% | -158.14% | -246.97% | -153.84% | -310.48% | -1,549.11% | -2,103.06% |
| EPS 2 | -5.400 | -3.540 | -2.030 | -2.740 | -1.820 | -2.402 | -3.280 | -3.311 |
| Free Cash Flow 1 | -56.91 | -14.8 | -50.25 | -67.16 | -1.608 | -137.5 | -133.4 | -122 |
| FCF margin | -279.46% | -42.97% | -136.04% | -162.19% | -3.49% | -333.54% | -1,096.76% | -1,276.86% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 3/5/20 | 3/4/21 | 3/3/22 | 3/2/23 | 3/7/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 11.54 | 9.294 | 11.56 | 10.01 | 10.53 | 7.683 | 9.105 | 15.2 | 14.03 | 11.68 | 9.044 | 8.666 | 8.339 | 10.6 | 10.6 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | 42 | - | - | - |
| EBIT 1 | -18.05 | -18.28 | -19.22 | -18.4 | -23.04 | -21.55 | -22.76 | -14.4 | -16.35 | -33.32 | -30.55 | -34.19 | -38.45 | -22.4 | -25.4 |
| Operating Margin | -156.36% | -196.73% | -166.16% | -183.76% | -218.7% | -280.54% | -249.98% | -94.71% | -116.58% | -285.18% | -337.85% | -394.48% | -461.04% | -211.32% | -239.62% |
| Earnings before Tax (EBT) 1 | -19.43 | -20.98 | -19.41 | -18.42 | -43.45 | -21.16 | -22.92 | -12.61 | -14.02 | -29.28 | -28.44 | -32.41 | -37.51 | -22.4 | -25.4 |
| Net income 1 | -19.43 | -20.98 | -19.41 | -18.42 | -43.45 | -21.16 | -22.92 | -12.61 | -14.1 | -29.28 | -28.44 | -32.41 | -37.51 | -22.4 | -25.4 |
| Net margin | -168.33% | -225.69% | -167.8% | -183.98% | -412.53% | -275.47% | -251.73% | -82.96% | -100.51% | -250.63% | -314.5% | -373.98% | -449.79% | -211.32% | -239.62% |
| EPS 2 | -0.5900 | -0.5600 | -0.5200 | -0.4900 | -1.160 | -0.5600 | -0.6100 | -0.3300 | -0.3300 | -0.5500 | -0.5400 | -0.6050 | -0.6967 | -0.4000 | -0.4500 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 3/3/22 | 5/4/22 | 8/3/22 | 11/2/22 | 3/2/23 | 5/3/23 | 8/2/23 | 11/1/23 | 3/7/24 | 5/8/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | - | - | - | - | 281 | 215 | 348 | 491 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -56.9 | -14.8 | -50.3 | -67.2 | -1.61 | -138 | -133 | -122 |
| ROE (net income / shareholders' equity) | - | - | - | - | -39% | -44.4% | -71.9% | -59.7% |
| ROA (Net income/ Total Assets) | - | - | - | - | -26.4% | -33.9% | -59.4% | -51.7% |
| Assets 1 | - | - | - | - | 267.8 | 377.3 | 317.2 | 388.5 |
| Book Value Per Share 2 | - | - | - | - | 5.430 | 3.510 | 5.470 | 6.670 |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | 0.21 | 0.36 | 0.16 | 2.15 | 3.48 | 3.8 | 2.43 | 3.4 |
| Capex / Sales | 1.05% | 1.05% | 0.42% | 5.19% | 7.57% | 9.22% | 20% | 35.59% |
| Announcement Date | 3/5/20 | 3/4/21 | 3/3/22 | 3/2/23 | 3/7/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
11.47
USD
Average target price
39.11
USD
Spread / Average Target
+240.99%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -51.84% | 597M | |
| +38.34% | 723B | |
| +34.28% | 595B | |
| -4.52% | 369B | |
| +20.05% | 332B | |
| +2.18% | 282B | |
| +17.02% | 244B | |
| +9.31% | 208B | |
| -5.07% | 205B | |
| -0.07% | 168B |
- Stock Market
- Equities
- EYPT Stock
- Financials EyePoint Pharmaceuticals, Inc.
